Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6 Thoracic 3 Head & Neck 3 Genitourinary 3 Gastrointestinal 2 CNS 2 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Gynecologic 1 Breast 1

Conditions

Interventions

pembrolizumab 12 Specimen Handling 8 Biopsy 8 Magnetic Resonance Spectroscopy 7 Paclitaxel 6 trastuzumab deruxtecan 4 Fluorouracil 4 Bevacizumab 4 durvalumab 3 Pemetrexed 3 Oxaliplatin 3 Leucovorin 3 Exercise 3 Cetuximab 3 Carboplatin 3 Capecitabine 3 Blood Specimen Collection 3 trametinib 2 olaparib 2 nilotinib 2 dostarlimab 2 cabozantinib 2 X-Rays 2 Temozolomide 2 Standard of Care 2 Radiosurgery 2 Nivolumab 2 Irinotecan 2 Cisplatin 2 zolbetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

relatlimab × Tumor-Agnostic × 30 days × Clear all

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡